Khuri FR - Search Results

1

Erratum: GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.

Koo J, Wang X, Owonikoko TK, Ramalingam SS, Khuri FR, Sun SY. Koo J, et al. Among authors: khuri fr. Oncotarget. 2021 Feb 2;12(3):251-252. doi: 10.18632/oncotarget.27752. eCollection 2021 Feb 2. Oncotarget. 2021. PMID: 33613851 Free PMC article.

2

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.

Koo J, Wang X, Owonikoko TK, Ramalingam SS, Khuri FR, Sun SY. Koo J, et al. Among authors: khuri fr. Oncotarget. 2015 Apr 20;6(11):8974-87. doi: 10.18632/oncotarget.3291. Oncotarget. 2015. PMID: 25797247 Free PMC article.

3

Lung cancer in the elderly: what's age got to do with it?

Owonikoko TK, Ramalingam SS, Khuri FR. Owonikoko TK, et al. Among authors: khuri fr. Oncology (Williston Park). 2010 Nov 15;24(12):1120, 1122, 1129. Oncology (Williston Park). 2010. PMID: 21141693 No abstract available.

4

Lung cancer: New biological insights and recent therapeutic advances.

Ramalingam SS, Owonikoko TK, Khuri FR. Ramalingam SS, et al. Among authors: khuri fr. CA Cancer J Clin. 2011 Mar-Apr;61(2):91-112. doi: 10.3322/caac.20102. Epub 2011 Feb 8. CA Cancer J Clin. 2011. PMID: 21303969 Free article.

5

The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer.

Steuer CE, Khuri FR, Ramalingam SS. Steuer CE, et al. Among authors: khuri fr. Cancer. 2015 Apr 15;121(8):E1-6. doi: 10.1002/cncr.29139. Epub 2014 Dec 17. Cancer. 2015. PMID: 25521095 Free article. Review.

6

Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.

Koo J, Wu X, Mao Z, Khuri FR, Sun SY. Koo J, et al. Among authors: khuri fr. J Biol Chem. 2015 May 29;290(22):14120-9. doi: 10.1074/jbc.M114.633057. Epub 2015 Apr 20. J Biol Chem. 2015. PMID: 25897075 Free PMC article.

7

The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.

Han B, Yao W, Oh YT, Tong JS, Li S, Deng J, Yue P, Khuri FR, Sun SY. Han B, et al. Among authors: khuri fr. Oncotarget. 2015 Jul 10;6(19):17532-42. doi: 10.18632/oncotarget.3947. Oncotarget. 2015. PMID: 26009898 Free PMC article.

8

Lung cancer in China: The new frontier?

Ramalingam SS, Khuri FR. Ramalingam SS, et al. Among authors: khuri fr. Cancer. 2015 Sep 1;121 Suppl 17:3058-60. doi: 10.1002/cncr.29569. Cancer. 2015. PMID: 26331811 Free article. No abstract available.

9

The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.

Yao W, Yue P, Khuri FR, Sun SY. Yao W, et al. Among authors: khuri fr. Oncotarget. 2015 Oct 27;6(33):34669-79. doi: 10.18632/oncotarget.5785. Oncotarget. 2015. PMID: 26415225 Free PMC article.

10

Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling.

Oh YT, Yue P, Wang D, Tong JS, Chen ZG, Khuri FR, Sun SY. Oh YT, et al. Among authors: khuri fr. Oncotarget. 2015 Dec 1;6(38):41324-38. doi: 10.18632/oncotarget.5847. Oncotarget. 2015. PMID: 26510914 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

479 results

Search Page